RMA normalization,which samples should be normalized together
0
0
Entering edit mode
@dipl-ing-johannes-rainer-846
Last seen 10.3 years ago
thank you naomi, this is exactly what i've done til now, first i have normalized each patient seperatly (or some patients together if i had three chips of one patient (as RMA works not so good with a small uneven number of chips)), and then when we finished to do the chips from all patients i normalized them all togehter. in the first analysis i searched for the genes that were regulated (bigger or smaller then M=1 (M=-1 respectively)) in most patients. the genes found by this method are fairly the same like those i got when normalizing all patients together and doing a wilcoxon test. that's all fine, but my boss was surprised to see that our replicates (=quality controls) looked better in the "single patient normalization way" than after normalizing all patients toghether. well, thanks for your answer, i think i will normalize all chips together and my boss has to accept that our controls are not as nice as they should be... thanks, jo Quoting Naomi Altman <naomi@stat.psu.edu>: > Dear Johannes, > Actually, technical replication is of little interest when you have > biological replication. If I understand your experiment, you have 40 > patients, each measured at 2 times. > > Because of the pairing, you have several options for appropriate > normalization and analysis: > > 1) Normalize the before and after for each patient together, and analyze M. > > You could use either RMA, or a simpler M vs A loess for this. > > 2) Normalize all the arrays together and then compute M for each patient. > > I would use RMA or gcRMA for this. > > In either case, I would simply use limma with the contrast > rep(1,npatients) since this gives the t-test for before-after which > seems to be of most interest. Limma has an advantage over ordinary > t-tests in that it combines some information across genes. However, > I expect it to be very similar to ordinary t-tests (or Wilcoxon > tests) because you have a fairly large sample size. Any of these > methods are appropriate. > > Incidentally, the technical reps are interesting for quality control, > but should not be included in this analysis. > > --Naomi > > At 09:48 AM 2/7/2005, Dipl.-Ing. Johannes Rainer wrote: >> thanks arne >> >> i have no replicates, affymetrix is still a little bit expensive ;) >> . all our chips were made by ourself and by looking at the >> histograms of the raw values there are no differences at all. in the >> whole experiment we made also two replicates, one with the same RNA, >> but different amount before amplification (one time 5 mug, the >> second time 1 mug) and the second replicate is RNA from the same >> patient, same time point, but the RNA was extracted by two different >> people not at the same time. if i normalize only those replicated >> chips i see nearly no differences between them (with a M (log2 >> regulation value) cut off of M=1 i get about 30 probe sets that >> differ), but when i normalize all 80 chips of all patients together >> the replicated chips show more differences... in my opinion i have >> to normalize all patient chips together, exspecially if i want to do >> for example a wilcox between all 0 hour and 6 hours chips. >> can you tell me a little bit more about the linear model you have >> used to merge the results? >> >> regards, jo >> >> >> Quoting Arne.Muller@sanofi-aventis.com: >> >>> Dear Johannes, >>> >>> I've a study with 84 affy chip to characterize a dose effect of a >>> drug. The study was conducted in 3 different laboratories. There >>> are strong differences betweent the laboratories and I've RMA >>> normalized per laboratory and then merged the results in a single >>> linear moel including the laboratory as an additional factor. Maybe >>> you can make the patient or source of RNA a random factor in a mixe >>> effects model - if you've replication per patient. >>> >>> Just looking at those genes with a significant dose effect I did >>> not find much differences between normalizing all chips together and >>> normalizing per laboratory. >>> >>> regards, >>> >>> Arne >>> >>> >>>> -----Original Message----- >>>> From: bioconductor-bounces@stat.math.ethz.ch >>>> [mailto:bioconductor-bounces@stat.math.ethz.ch]On Behalf Of Dipl.-Ing. >>>> Johannes Rainer >>>> Sent: 07 February 2005 10:13 >>>> To: bioconductor@stat.math.ethz.ch >>>> Subject: [BioC] RMA normalization,which samples should be normalized >>>> together >>>> >>>> >>>> hi, >>>> we are interested in the response of patients to a special treatment, >>>> so we have patient samples before and after treatment. i have >>>> normalized this samples in different ways using RMA. As RMA tries to >>>> detect and correct probe effects by looking at the expresison >>>> levels of >>>> the probes across all chips it is not surprising that the outcome of >>>> the analysis differs depending on which chips i normalize together. >>>> It is clear that i have to normalize all patient samples >>>> together if i >>>> want to compare the expression values of the genes (lets say using >>>> statistical tests). i am also analyzing the chips using the 'old >>>> fashioned way' by using M and A values and i suppose it is not >>>> problematic at all to compare M values of lets say patient 1, 6 hours >>>> sample against 0 hours sample with those from patient 2, also 6 hours >>>> versus 0 hours where the chips from the two patients were NOT >>>> normalized together. >>>> >>>> -now my question is if someone else has experience in what samples >>>> could and should be normalized together with RMA. I saw that ther are >>>> (big) differences in the regulation (M) values if i normalize two >>>> different patients together compared with the values that i >>>> get when i >>>> normalize only samples from the same patients together. >>>> >>>> thanks in advance >>>> >>>> _______________________________________________ >>>> Bioconductor mailing list >>>> Bioconductor@stat.math.ethz.ch >>>> https://stat.ethz.ch/mailman/listinfo/bioconductor >> >> _______________________________________________ >> Bioconductor mailing list >> Bioconductor@stat.math.ethz.ch >> https://stat.ethz.ch/mailman/listinfo/bioconductor > > Naomi S. Altman 814-865-3791 (voice) > Associate Professor > Bioinformatics Consulting Center > Dept. of Statistics 814-863-7114 (fax) > Penn State University 814-865-1348 (Statistics) > University Park, PA 16802-2111 > > > ----- End forwarded message -----
Normalization probe affy limma gcrma DOSE Normalization probe affy limma gcrma DOSE • 1.8k views
ADD COMMENT

Login before adding your answer.

Traffic: 542 users visited in the last hour
Help About
FAQ
Access RSS
API
Stats

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6